CORCEPT THERAPEUTICS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Cost of revenue | $13.0M | $10.9M | $6.5M | $5.4M | $5.3M |
| Cash from operations | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M |
| Capital expenditure | $211,000 | $2.2M | $139,000 | $413,000 | $469,000 |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M |
| Share repurchases | $172.9M | $15.7M | $0 | $0 | — |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
Shares outstanding 107.4M · Free float 87.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.